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DCs are located throughout mucosal surfaces 
and orchestrate the delicate balance between 
tolerance to innocuous antigens and the gen-
eration of protective immune responses upon 
exposure to pathogens. Different DC sub-
sets populate the gut mucosa and mesenteric 
lymph  nodes  (mLNs),  and  their  functions 
vary according to their anatomical location 
and conditioning by epithelial cells (Iwasaki, 
2007).  For  instance,  CD103+  and  CD103 
DC subsets isolated from mLNs display distinct 
phenotypes and cytokine profiles. A substan-
tial proportion of CD103+ DCs continuously 
emigrate from the intestine to the mLNs in a 
CCR7-dependent  manner  (Johansson-Lind-
bom et al., 2005; Jang et al., 2006), where they 
represent from 40 to 70% of the DC popu-
lation (Coombes et al., 2007; Jaensson et al., 
2008). Under steady-state conditions, mLN 
CD103+ DCs are prone, in the presence of 
retinoic acid, to convert naive CD4+CD25 
T cells into CD4+CD25+Foxp3+ T reg cells 
(Coombes  et  al.,  2007;  Sun  et  al.,  2007), 
whereas CD103 DCs isolated from the mLNs 
and lamina propria (LP) of the small intestine 
express  CX3CR1  and  drive  Th17  polariza-
tion in vitro (Denning et al., 2007; Atarashi 
et al., 2008). The mLN CD103 DCs appear 
to be directly derived from blood-borne pre-
cursors; express Toll-like receptor (TLR) 2, 
TLR4, and TBX21 to a greater extent than 
CD103+ DCs; and secrete high levels of TNF 
and IL-6 in response to stimulation (Coombes 
and Powrie, 2008). However, little is known 
about the precise contribution of each of these 
DC subsets during the development of intesti-
nal inflammation.
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Mesenteric lymph node (mLN) CD103 (E integrin)+ dendritic cells (DCs) induce regulatory 
T cells and gut tolerance. However, the function of intestinal CD103 DCs remains to be 
clarified. CD47 is the ligand of signal regulatory protein  (SIRP) and promotes SIRP+ 
myeloid cell migration. We first show that mucosal CD103 DCs selectively express SIRP 
and that their frequency was augmented in the lamina propria and mLNs of mice that 
developed Th17-biased colitis in response to trinitrobenzene sulfonic acid. In contrast, the 
percentage of SIRP+CD103 DCs and Th17 responses were decreased in CD47-deficient 
(CD47 knockout [KO]) mice, which remained protected from colitis. We next demonstrate 
that transferring wild-type (WT), but not CD47 KO, SIRP+CD103 DCs in CD47 KO mice 
elicited severe Th17-associated wasting disease. CD47 expression was required on the 
SIRP+CD103 DCs for efficient trafficking to mLNs in vivo, whereas it was dispensable on 
both DCs and T cells for Th17 polarization in vitro. Finally, administration of a CD47-Fc 
molecule resulted in reduced SIRP+CD103 DC–mediated Th17 responses and the protec-
tion of WT mice from colitis. We thus propose SIRP+CD103 DCs as a pathogenic DC 
subset that drives Th17-biased responses and colitis, and the CD47–SIRP axis as a poten-
tial therapeutic target for inflammatory bowel disease.
© 2009 Fortin et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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RESULTS
CD47 regulates SIRP+CD103 DC homeostasis in the LP 
and mLNs of naive and TNBS-treated mice
Multiple DC subpopulations have been identified and char-
acterized by their expression of CD11c, CD11b, and CD103 
in the intestinal LP and mLNs. Because CD47 has previously 
been shown to regulate cell migration of innate SIRP+ cells 
(Liu et al., 2002; Van et al., 2006), we first thought to exam-
ine the expression of SIRP on the two major mucosal DC 
subsets, i.e., CD103+ and CD103 DCs. We found that 
SIRP was preferentially expressed with high intensity on 
CD11b+CD103 DCs in the LP and mLNs (Fig. 1, A and B). 
To investigate the dynamic regulation of these DC subsets 
during inflammation, their distribution profiles were as-
sessed at steady state and in response to TNBS challenge. We 
observed an increased percentage of SIRP+CD103 DCs in 
the LP as well as in the mLNs after the intrarectal administra-
tion of TNBS (Fig. 1, A and B), suggesting a role for this DC 
subset in the response to hapten-induced colonic inflamma-
tion. We next used CD47 KO mice to examine the potential 
role of CD47 in modulating the frequency of SIRP+CD103 
DCs in the LP and mLNs. Although no significant differ-
ences in SIRP+CD103 DC proportions were observed   
in the LP of naive WT and CD47 KO mice (Fig. 1, A and C), 
a reduction in SIRP+CD103 DCs was observed in the 
mLNs of naive CD47 KO mice when compared with their 
WT littermates (Fig. 1, B and D). Upon TNBS challenge, 
the increase in SIRP+CD103 DCs normally observed in 
WT mice did not occur in either the LP or the mLNs of 
CD47 KO mice (Fig. 1, C and D), suggesting that CD47 is 
required for the mobilization of SIRP+CD103 DCs in re-
sponse to TNBS challenge. Although we show results from 
mLNs on day 2 after TNBS instillation, similar data were ob-
served on day 4 and in caudal lymph nodes (unpublished 
data).  Notably,  the  proportion  of  SIRPCD103+  DCs, 
which have been shown to promote tolerance, were not   
increased in the LP of either strain of TNBS-treated mice. 
However, their frequency was strongly reduced in the mLNs 
of WT but not CD47 KO TNBS-treated mice (Fig. S1). Of 
note, the intensity of CD47 expression was identical between 
SIRP+CD103 and SIRPCD103+ DCs in the LP and 
mLNs of WT mice (unpublished data). Collectively, our re-
sults suggest that CD47 regulates the mobilization of mucosal 
SIRP+CD103DCs in response to inflammation and, thus, 
may play a role in gut DC homeostasis.
CD47 ablation ameliorates the development  
of chronic TNBS colitis
We therefore hypothesized that the increased proportion of 
SIRP+CD103 DCs in the LP and mLNs of WT mice 
would be correlated with colitis development, in which case 
CD47 KO mice would be protected from disease. Analysis 
of body weight loss as early as day 2 after primary TNBS in-
stillation revealed a significant reduction of wasting disease 
in CD47 KO compared with WT mice (Fig. 2 A). This 
protection was enhanced daily until day 8, by which time 
Crohn’s disease (CD) is a chronic, relapsing, T cell–driven 
inflammatory disease of the gastrointestinal tract thought to 
result from inappropriate mucosal immune responses to com-
mensal bacteria in genetically susceptible individuals (Cho, 
2008). DCs have been implicated in CD pathogenesis, be-
cause dysregulation in DC–epithelial cell interactions, defec-
tive migration and function of tolerogenic DCs, and/or 
aberrant immunogenic DC responses to pathogens have been 
proposed to participate in the induction of intestinal inflam-
mation (Kelsall, 2008). Once initiated, the inflamed tissue is 
characterized by the expression of innate (IL-6, IL-12, TNF, 
and IL-23) and adaptive-derived (IL-6, IFN-, and IL-17) 
proinflammatory  cytokines  (Sanchez-Munoz  et  al.,  2008). 
Antigen-presenting cell–derived TGF-, IL-1, IL-6, and 
IL-23 drive Th17 responses, whereas IL-12 and IFN- pro-
mote Th1 and suppress Th17 responses (Trinchieri, 1993; 
Bettelli et al., 2007).
Trinitrobenzene sulfonic acid (TNBS)–induced colitis 
is a mouse model of intestinal inflammation sharing many 
key features with human CD. TNBS administration first 
induces acute inflammation, characterized by the infiltra-
tion of neutrophils and macrophages, followed by antigen-
specific priming of T cells. Challenge with a second dose of 
TNBS provokes a T cell–predominant reaction associated 
with tissue damage and mimics the chronic inflammation 
seen in CD (te Velde et al., 2006). Although classically 
considered a Th1 disease, the recently identified Th17 cell 
lineage appears to play an important role in the develop-
ment of both TNBS colitis and CD (Annunziato et al., 
2007; Sheibanie et al., 2007).
CD47, a marker of self on immune and nonimmune 
cells, is implicated at several levels in the generation of im-
mune responses (van den Berg and van der Schoot, 2008). 
On the one hand, ligation of CD47 by the extracellular ma-
trix protein thrombospondin-1, which is abundantly and 
rapidly expressed in tissues in response to inflammation 
(Reed et al., 1993), down-regulates IL-12p70 production by 
antigen-presenting cells (Armant et al., 1999) and impairs 
human naive T cell differentiation to Th1 cells in vitro with-
out any immune deviation to Th2 cells (Avice et al., 2000). 
Recent data have also shown that CD47 expression on T 
cells is a self-control negative regulator of Th1 immune re-
sponses in vivo (Bouguermouh et al., 2008). On the other 
hand,  CD47  interacts  with  signal  regulatory  protein   
(SIRP), its counterreceptor, which is selectively expressed 
on myeloid, endothelial, and neuronal cells (Adams et al., 
1998; Ticchioni et al., 2001). The expression of CD47 on 
epidermal and dermal DCs promotes their migration to 
draining lymph nodes, where T cell priming and immune 
responses are initiated (Van et al., 2006). We first show that 
SIRP is selectively expressed on one of the two major mu-
cosal DC subsets, i.e., the CD103 DCs. We next demon-
strate that SIRP+CD103 DCs are the primary immunogenic 
DC subset involved in the development and perpetuation of 
Th17-associated TNBS-induced colitis, and that their mi-
gration is controlled by CD47.JEM VOL. 206, August 31, 2009 
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mice with TNBS colitis displayed shortening and thicken-
ing, with patchy areas of severe ulceration and prominent 
adhesions typical of this form of colitis. On the contrary, 
CD47 KO mice developed fewer of these characteristics and 
CD47 KO, as opposed to WT mice, had fully regained their 
original body weight (Fig. 2 A). To evaluate the degree of 
colonic inflammation, both the macroscopic and histological 
scores of tissue damage were assessed. Colons from WT 
Figure 1.  CD47 regulates SIRP+CD103 DC homeostasis in the LP and mLNs. (A–D) CD11b, CD103, and SIRP expression among CD45.2+CD11cHi  
DCs at steady state (control; top) and 2 d after intrarectal administration of 3 mg TNBS (TNBS; bottom) in the LP (A and C) and mLNs (B and D) of WT  
(A and B) and CD47 KO (C and D) mice. Data shown are one representative mouse per group. (E) Percentage of SIRP+CD103 DCs among CD45.2+CD11cHi  
DCs in the LP (left) and mLNs (right). Data represent the means ± SEM of more than eight mice per group. Each experiment was independently performed  
a minimum of four times. *, P < 0.05; **, P < 0.01; ***, P < 0.001.1998 CD47 GOVERNS SIRP+ DC HOMING AND COLITIS | Fortin et al.
Figure 2.  CD47 ablation protects from the development of TNBS colitis. TNBS colitis was induced on day 0 alone or on days 0 and 7 (circled).  
(A) Weight loss curves of WT and CD47 KO mice injected intrarectally with saline (control), ethanol alone, or TNBS dissolved in 50% ethanol on day 0. (B–E) 
Macroscopic (B and D) and histological (C and E) analyses of inflammation in WT and CD47 KO mice. Data represent means ± SEM of more than eight mice 
per group, and one representative experiment out of three is shown. (F) Weight loss curves of WT and CD47 KO mice injected intrarectally with 2 mg TNBS 
dissolved in 50% ethanol on days 0 and 7. (G and H) Macroscopic (G) and histological (H) analyses of inflammation in WT and CD47 KO mice after reinduc-
tion of TNBS colitis. Data represent means ± SEM of six mice per group. One representative experiment out of three is shown. *, P < 0.05; **, P < 0.01.
displayed significantly milder inflammation than WT mice 
(Fig. 2, B and D). Upon histological assessment, we con-
firmed that colons from WT mice with colitis exhibited a 
substantial infiltration with mononuclear cells, edema, and 
loss of goblet cells, whereas CD47 KO mice were resistant 
to these changes (Fig. 2, C and E).JEM VOL. 206, August 31, 2009 
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shift in the Th1/Th17 paradigm reported in TNBS colitis 
(Sheibanie et al., 2007). Thus, CD47 ablation impairs the in-
duction and perpetuation of colitis associated with a Th17-
biased response in mLNs.
SIRP+CD103 DCs promote Th17 responses in vitro
To establish causative links between the increased frequency 
of mucosal SIRP+CD103 DCs and Th17 responses ob-
served in vivo, we first sought to assess the in vitro Th1- 
versus Th17-promoting capacities of SIRP+CD103 and 
SIRPCD103+ DCs. These two DC subpopulations were 
isolated from the LP and mLNs (Fig. S2) and co-cultured 
with CD4+ T cells from the same anatomical origin. We 
found that SIRP+CD103 DCs were more efficient than 
SIRPCD103+ DCs at promoting IL-17 production by 
CD4+ T cells (Fig. 4, A and B). Interestingly, DCs purified 
from spleens behaved in a very similar manner as those iso-
lated from LP and mLNs, with SIRP+CD103 DCs favor-
ing Th17 (Fig. 4 C).
When bone marrow–derived DCs (BMDCs) that express 
SIRP (>99%) but not CD103 (<1%) were co-cultured with 
naive transgenic T cells under Th17-promoting conditions, 
they elicited a similar Th17-biased profile as SIRP+CD103 
mLN DCs, suggesting that these properties are not limited   
to gut-derived DCs (Fig. 4 D). Moreover, SIRP+CD103 
mucosal or splenic DCs and SIRP+CD103 BMDCs in-
duced statistically equivalent IL-17+/IFN-+ ratios, both 
of which were significantly higher compared with sorted 
SIRPCD103+ DCs (Fig. 4 E). Therefore, we propose that 
SIRP+CD103  but  not  SIRPCD103+  DCs  possess 
Th17-promoting properties in vitro.
Transfer of SIRP+CD103 BMDCs induces colitis  
and promotes a Th17 response in CD47 KO mice
To  directly  examine  the  proinflammatory  capacity  of 
SIRP+CD103 DCs in vivo and the role of CD47 on the 
DCs for disease induction, CD47 KO mice were adminis-
tered mature WT or CD47 KO SIRP+CD103 BMDCs 
on the day of colitis induction. BMDCs were injected i.p. 
because previous reports have shown that the mLNs drain 
the peritoneal cavity, in addition to the gut tissues (Johansson-
Lindbom et al., 2003; Kool et al., 2008). Moreover, the i.v. 
route was deemed unsuitable because i.v.-injected BMDCs 
migrate very poorly to the LNs, even when administered at 
high  concentrations  (3–8  ×  106  BMDCs/mouse;  Robert   
et al., 2003; Cavanagh et al., 2005). Upon reinduction of 
TNBS colitis on day 8, CD47 KO mice injected with WT 
BMDCs developed severe wasting disease (Fig. 5 A), indi-
cating that CD47 expression was not required in the host for 
colitis development. Injection of WT BMDCs had no effect 
on disease outcome when injected in WT mice (Fig. S3). In 
contrast to WT BMDCs, injection of CD47 KO BMDCs in 
CD47 KO hosts appeared to induce only a mild form of in-
flammation that resulted in a slight, nonsignificant reduction 
of body weight (Fig. 5 A). The changes in body weight were 
reflected both in the macroscopic (Fig. 5 B) and microscopic 
We next confirmed the disease resistance of CD47 KO 
mice in a reactivated form of colitis, where a second instilla-
tion of TNBS was administered 7 d after the primary instilla-
tion. This model is said to mimic the relapsing behavior of 
human CD. Here, upon reinduction of TNBS colitis, CD47 
KO mice remained resistant to body weight loss, whereas WT 
mice displayed severe wasting once again (Fig. 2 F). Macro-
scopic (Fig. 2 G) and microscopic (Fig. 2 H) scores confirmed 
that CD47 KO mice were largely devoid of signs of chronic 
colonic  inflammation.  Collectively,  our  data  demonstrate 
that the CD47-dependent increase in SIRP+CD103 DCs 
in the LP and mLNs is correlated with the development of 
chronic intestinal inflammation.
CD47 ablation impairs Th17 responses in vivo
The chronic stage of TNBS colitis is driven by an important 
interplay between the innate and adaptive immune systems. 
We sought to further characterize this inflammation in WT 
and CD47 KO mice. Both on day 8 and after reinduction of 
TNBS colitis, a strong up-regulation of IL-6 mRNA ex-
pression was observed in WT but not in protected CD47 
KO mice (Fig. 3 A). The same trend, but of a lesser magni-
tude, was observed for TGF-, IL-12p35, and IL-23p19, 
where mRNA expression was increased in TNBS-treated 
WT but not CD47 KO mice (Fig. 3 A). Corroborating the 
increase in IL-6 and TGF- expression, IL-17 mRNA was 
highly up-regulated at both time points in WT but not in 
CD47 KO mice (Fig. 3 B). IFN- mRNA expression was 
greater in CD47 KO than WT mice, but only on day 8, with 
no significant difference observed after reinduction (Fig. 3 B). 
Interestingly, although both forms of colitis displayed quali-
tatively and quantitatively distinct IL-17 and IFN- mRNA 
expression profiles, the IL-17/IFN- mRNA expression ra-
tios were nearly identical, with both being higher in WT 
than CD47 KO mice (Fig. 3 C). We therefore chose to fo-
cus on the reinduction model of colitis for the rest of this 
study because it more accurately reflects the chronic relaps-
ing behavior of CD.
We next postulated that the reduction in IL-17–associ-
ated cytokines in colon tissues was partly attributable to an 
impaired capacity to generate IL-17–producing T cells (Th17 
cells) in the mLNs of CD47 KO mice. Therefore, we exam-
ined IFN- and IL-17 production in 4-d cultures of mLNs 
isolated from mice with chronic TNBS colitis. Analysis by 
flow cytometry revealed that the percentage of Th17 cells 
was significantly higher in WT compared with CD47 KO 
mice with colitis (Fig. 3 D). Similar data were observed by 
measuring IL-17 production in the culture supernatants by 
ELISA or by examining IL-17 expression in mLN cells after 
6 h of PMA/ionomycin restimulation (unpublished data). 
Under these pro-Th17 culture conditions, no significant dif-
ference was observed with respect to CD4+ T cells producing 
IFN- (Fig. 3 D). When expressed as a ratio of IL-17+/IFN-+ 
cells, CD47 KO mice exposed to TNBS displayed a signifi-
cantly reduced propensity toward IL-17 production (Fig. 3 E), 
corroborating with tissue mRNA expression and the recent 2000 CD47 GOVERNS SIRP+ DC HOMING AND COLITIS | Fortin et al.
(uninjected, <5%; CD47 KO BMDCs, 25%; and WT BM-
DCs, 45%).
We next examined whether disease development after   
WT BMDC injection was associated with the induction of 
(Fig. 5 C) extent of inflammation, with WT BMDC injec-
tion resulting in an aggressive form of disease. Notably, in-
jection of WT BMDCs also increased the mortality rate of 
CD47 KO mice more than injection of CD47 KO BMDCs 
Figure 3.  Decreased proinflammatory cytokine and Th17-biased responses in CD47 KO mice. (A–C) Colonic mRNA expression of cytokines.  
(A) Colonic IL-6, IL-12p35, TGF-, and IL-23p19 mRNA expression. (B) Colonic IL-17 and IFN- mRNA expression. (C) Ratio of colonic IL-17/IFN- mRNA 
expression. Data represent mean fold changes relative to WT control ± SEM of more than eight mice per group (two independent experiments). (D) mLNs 
were isolated after reinduction of TNBS colitis and stimulated for 4 d in the presence of IL-23. Intracytoplasmic staining was performed after restimula-
tion. The percentage IL-17+ or IFN-+ cells among total CD4+ T cells is shown. (E) Ratio of IL-17+/IFN-+ cells among CD4+ T cells. Data represent the 
mean percentages ± SEM of more than seven mice per group (two independent experiments). *, P < 0.05; **, P < 0.01.JEM VOL. 206, August 31, 2009 
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cytokine (Fig. 5 D). Therefore, only WT BMDCs resulted   
in  a  significant  increase  in  the  IL-17/IFN-  mRNA  ratio   
(Fig. 5 D). To verify whether the induction of colonic IL-17 
mRNA expression was linked to an increase in Th17 cells, we 
Th17-biased responses in CD47 KO hosts. Injection of WT 
BMDCs significantly enhanced the colonic mRNA expression 
of IL-17 but not IFN-, whereas injection of CD47 KO BM-
DCs had no effect on the colonic mRNA expression of either 
Figure 4.  SIRP+CD103 DCs promote Th17 responses in vitro. (A–C) Percentage of SIRP+CD103 and SIRPCD103+ DCs (gated on CD11cHi; 
left) and their IFN-– versus IL-17–promoting capacities (middle and right) when isolated from the LP (A), mLNs (B), or spleen (C) and co-cultured with 
purified anti-CD3–stimulated CD4+ T cells of the same anatomical origin. Dot plots represent one independent experiment out of two or three. (D) Per-
centage of SIRP+CD103 and SIRPCD103+ BMDCs (gated on CD11c+; left) and co-culture with OVA-stimulated CD4+ transgenic T cells under Th17-
polarizing conditions (right). Data represent one independent experiment out of three. (E) IL-17+/IFN-+ cell ratio (among CD4+ T cells) after co-culture 
with either sorted SIRP+CD103 or SIRPCD103+ DCs or SIRP+CD103 BMDCs. The data of sorted cells represents mean of all sources of DCs  
(LP, mLNs, and spleen) ± SEM of a minimum of three independent experiments. *, P < 0.05.2002 CD47 GOVERNS SIRP+ DC HOMING AND COLITIS | Fortin et al.
Figure 5.  CD47 expression on SIRP+CD103 DCs promotes the development of intestinal inflammation and Th17 responses. CD47 KO mice were 
injected i.p. with saline or WT or CD47 KO BMDCs 30 min before the induction of TNBS colitis on day 0. TNBS was reinduced on day 8. (A) Weight-loss curves 
after transfer of WT or CD47 KO BMDCs in CD47 KO hosts and reinduction of TNBS colitis, normalized to body weight on day 8. (B and C) Macroscopic (B) and 
histological (C) appearance of colonic inflammation. Images are of one representative mouse per experimental group. (D) Colonic mRNA expression of IL-17 
and IFN- and IL-17/IFN- mRNA expression ratio. Data represent the mean fold changes relative to control. (E) mLNs were isolated after reinduction of TNBS 
colitis and stimulated for 4 d in the presence of IL-23. The percentages of IL-17+ or IFN-+ CD4+ T cells and the ratio of IL-17+/IFN-+ cells among CD4+ T cells 
are shown. Data represent means ± SEM of more than five mice per group (two pooled independent experiments). *, P < 0.05; ***, P < 0.001.
examined the mLNs of reconstituted mice. Injection of WT 
BMDCs increased the proportion of IL-17+ CD4+ T cells, 
leading to a significant enhancement in the IL-17+/IFN-+ 
CD4+ T cell ratio (Fig. 5, E and F). On the other hand, injec-
tion of CD47 KO BMDCs elicited IL-17 expression that did 
not translate into a significant increase in the IL-17/IFN-  JEM VOL. 206, August 31, 2009 
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SIRP–CD47 axis on the recruitment of SIRP+CD103 
DCs in mLNs, Th17 polarization, and the development of 
chronic colitis in WT mice. To this end, BALB/c mice were 
administered a CD47-Fc molecule i.p. 30 min before TNBS 
injection and on days 1–3 (Fig. 7 A, arrows). Mice adminis-
tered CD47-Fc were largely protected from colonic inflamma-
tion as assessed by body weight, starting as early as 1 d after the 
induction of colitis (Fig. 7 A). Furthermore, CD47-Fc–treated 
mice remained resistant to colitis even after a second induction 
of TNBS colitis, as demonstrated by a reduction in body 
weight loss and the extent of tissue damage (Fig. 7, A–C). In-
jection of a control human CD47-Fc with no cross-reactivity 
in mice did not ameliorate disease (not depicted). Serum levels 
and colonic mRNA expression of IL-6 were determined early 
in disease onset (day 4) and were dramatically reduced in 
CD47-Fc–treated mice (Fig. 7 D). Importantly, the percentage 
of SIRP+CD103 DCs was specifically and significantly re-
duced by CD47-Fc treatment (Fig. 7 E). On day 4, IL-17 and 
IFN- mRNA expression were unaffected. After reinduction, 
IL-17 mRNA expression was effectively suppressed by CD47-
Fc, whereas IFN- mRNA expression was unaltered (Fig. 7 F). 
Regardless of the time of sacrifice (day 4 or after reinduction), 
the IL-17/IFN- mRNA ratio was nearly identical and equally 
suppressed by administration of CD47-Fc (Fig. 7 G). Similarly, 
the Th17/Th1 ratio in mLNs was also reduced by CD47-Fc 
(unpublished data). We therefore conclude that CD47-Fc 
treatment protects mice from the development of chronic   
colitis and is correlated with an altered development of 
SIRP+CD103 DC–mediated Th17 responses.
DISCUSSION
DCs lie at the interface between the innate and the adaptive 
immune system, and although they are poised to maintain gut 
homeostasis and tolerance, they also appear to play a critical 
role in CD pathogenesis. In this paper, we propose SIRP-
expressing CD11b+CD103 DCs as one primary candidate 
for the induction and perpetuation of chronic TNBS colitis 
and implicate CD47 as a key player in controlling their ho-
meostasis and trafficking to the LP and mLNs. We first ob-
served a correlation between the frequency of SIRP+CD103 
DCs in the LP and mLNs, Th17 responses, and the develop-
ment of intestinal inflammation, parameters that were all im-
paired in CD47 KO mice. Next, we demonstrated that CD47 
expression is required on SIRP+CD103 DCs for efficient 
trafficking to mLNs and induction of severe wasting Th17-
associated disease in vivo, but is dispensable on both SIRP+ 
DCs and T cells to promote Th17 responses in vitro. Finally, 
early administration of a CD47-Fc molecule treated and pre-
vented the recurrence of experimental colitis, which was cor-
related with defective homing of SIRP+CD103 DCs and 
Th17 responses. We thus provide evidence that CD47 ex-
pression on SIRP+CD103 DCs governs their trafficking 
and DC-driven Th17 responses, which are likely implicated 
in the development of intestinal inflammation.
Although the importance of DCs in the initiation of in-
testinal inflammation is now well accepted (Coombes and 
ratio (Fig. 5, E and F). Finally, SIRP+CD103 DCs purified 
from WT mLNs and injected i.p. were also capable of induc-
ing severe wasting disease, resulting in 25% mortality after a 
single dose of TNBS in CD47 KO mice (Fig. S4). Severe 
weight loss in these mice was correlated with pronounced co-
lonic inflammation and Th17-polarized responses, corroborat-
ing the similar in vitro pro-Th17 responses of SIRP+CD103 
BMDCs and mucosal DCs. These data demonstrate that CD47 
expression is dispensable on the endothelium, epithelium, and 
T cells of the host but appears to be critical on SIRP+CD103 
DCs for Th17-associated colonic disease induction in vivo.
SIRP+CD103 DC trafficking but not phenotype  
or function is governed by CD47
We next sought to delineate the mechanisms by which CD47 
expression on SIRP+CD103 BMDCs controls the devel-
opment of Th17 responses and colonic inflammation. To this 
end, we evaluated the in vivo migratory properties and the in 
vitro function of WT and CD47 KO BMDCs. First, WT and 
CD47 KO BMDCs were fluorescently labeled and injected 
i.p. at a 1:1 ratio in CD47 KO mice and retraced in the mLNs 
after 2 d. By using this competitive migration assay, we pro-
vide evidence that CD47 expression on BMDCs significantly 
favors their accumulation in the mLNs (Fig. 6, A and B), cor-
roborating  the  increased  mobilization  of  SIRP+CD103 
mucosal DCs observed in WT but not CD47 KO mice upon 
induction of TNBS colitis (Fig. 1).
Next, we assessed the phenotype of BMDCs in terms of 
their expression of CD11c, CD11b, SIRP, and CD103 and 
observed no difference between WT and CD47 KO BM-
DCs (Fig. 6 C). Importantly, the level of expression of SIRP 
was not altered on a per-cell basis by the expression of CD47, 
as determined by its mean fluorescence intensity (Fig. 6 C). 
The surface expression of MHC II and the co-stimulatory 
molecules CD40 and CD86 were also independent of CD47 
expression (Fig. 6 D). We next examined the function of 
WT and CD47 KO BMDCs by measuring the production of 
cytokines such as IL-6 and IL-23p19, as well as their ability 
to drive Th17 polarization. Both cytokine production and Th17-
promoting capacity were found to be unrelated to CD47 ex-
pression on the DCs (Fig. 6, E and F). Also, lack of CD47 
expression on T cells did not alter the percentage of IL-17–
producing CD4+ T cells, thereby eliminating the possibility 
of a T cell–intrinsic defect in Th17 polarization in CD47 KO 
T cells as a mechanism for decreased Th17 responses (Fig. 6 F). 
Because CD47 does not alter the phenotype, activation sta-
tus, cytokine production, or Th17-polarizing capacity of SIRP+ 
CD103 BMDCs, we propose that CD47 expression on 
SIRP+CD103  DCs  is  critical  for  their  trafficking  to 
mLNs, a property mechanistically related to the ensuing 
Th17 responses and colitis development.
Administration of CD47-Fc ameliorates disease development 
in BALB/c mice
Finally, we circumvented the multiple defects of CD47 KO 
hosts and directly examined the impact of targeting the 2004 CD47 GOVERNS SIRP+ DC HOMING AND COLITIS | Fortin et al.
SIRP expression on mucosal CD103 DCs and to support 
a role for this DC subset in the in vivo promotion of intestinal 
inflammation. Nevertheless, although the proportion of total 
Powrie, 2008), the specific contributions of individual DC 
subsets and the key molecules involved in their function/mi-
gration remain to be clarified. This is the first study to identify 
Figure 6.  CD47 regulates SIRP+CD103 DC trafficking but not phenotype or function. (A, left) 1:1 ratio of labeled BMDCs before injection on 
day 0. (middle and right) TNBS colitis was induced in CD47 KO mice, and mLNs were harvested after 2 d. (middle) CD11c+ DCs in the mLNs of uninjected 
CD47 KO mice. (right) Labeled WT and CD47 KO BMDCs (gated on CD11c+) in the mLNs of BMDC-injected CD47 KO mice. One representative mouse is 
shown for each condition. (B) Percentages of labeled WT and CD47 KO BMDCs (gated on CD11c+) in the mLNs of CD47 KO mice. Data were generated in 
two independent experiments (n = 8). (C and D) Analysis of phenotype (C) and activation status (D) of LPS-stimulated BMDCs. The numbers in brackets in 
C represent the mean fluorescence intensity of SIRP. Data are representative of three independent experiments. (E) Cytokine production by BMDCs 
stimulated overnight with LPS (0–100 ng/ml) and IFN- (10 ng/ml) in vitro. Data represent the means ± SEM (n = 4 independent experiments). (F) Per-
centage of IL-17+ cells (among CD4+ T cells) after criss-cross co-cultures with anti-CD3–stimulated WT versus CD47 KO splenic CD4+ T cells and LPS-
stimulated WT versus CD47 KO BMDCs under Th17-polarizing conditions. Data represent means ± SEM (n = 3 independent experiments with two to 
three mice per experimental group).JEM VOL. 206, August 31, 2009 
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have been postulated that the reduction in the proportion of 
CD103+ DCs migrating to the mLNs of WT mice was the key 
event in triggering intestinal inflammation, as opposed to the 
increased recruitment of the pathogenic SIRP+CD103 DC 
SIRP+CD103 DCs increased in the LP and mLNs of WT 
mice upon induction of TNBS colitis, the percentage of the 
tolerogenic CD103+ DC subset, which we describe as being 
primarily SIRP, decreased in the mLNs. Therefore, it may 
Figure 7.  Administration of CD47-Fc protects BALB/c mice from the development of TNBS colitis. WT BALB/c mice were injected i.p. with saline 
or CD47-Fc, TNBS colitis was induced on days 0 and 8 (circles), and mice were sacrificed on day 4 or 12 (after reinduction). (A) Weight-loss curves normal-
ized to body weight on day 0. (B) Macroscopic appearance and (C) mean macroscopic score inflammation. (D) Serum concentration (top) and colonic mRNA 
expression (bottom) of IL-6. (E) mLN SIRP+CD103 DCs as a percentage of total CD11cHi. (F) Colonic mRNA expression of IL-17 and IFN-. (G) IL-17/IFN- 
mRNA expression ratio. Data represent means ± SEM of more than six mice per group of two independent experiments. *, P < 0.05; **, P < 0.01.2006 CD47 GOVERNS SIRP+ DC HOMING AND COLITIS | Fortin et al.
inflammatory conditions, CD47 may be implicated in the 
recruitment of SIRP+CD103 DC precursors to the LP 
and/or the mLNs, resulting in a reduction in the frequency 
of  SIRP+CD103  DCs  at  those  sites  in  CD47  KO  or 
CD47-Fc–treated mice. Nevertheless, we cannot exclude 
the possibility that CD47 is required for the migration of 
SIRP+CD103 DCs directly from the LP to the mLNs 
(Fig. S5). Thus, further examination of the physiological 
routes of SIRP+CD103 DC trafficking under inflamma-
tory conditions is required to delineate the precise role of 
CD47 in this process.
The early phases of TNBS colitis have been successfully 
induced in the absence of T cells. Therefore, innate-mediated 
mechanisms are also likely to be implicated in disease patho-
genesis (Fiorucci et al., 2002; Katakura et al., 2005). SIRP+ 
neutrophils, which are rapidly recruited to sites of inflamma-
tion, have been shown to exhibit CD47-mediated transmi-
gration (Cooper et al., 1995). A significant reduction in 
colonic myeloperoxidase activity, a marker of neutrophil in-
filtration, occurred early in disease development in CD47 KO 
mice (unpublished data). We thus hypothesized that a defect 
in CD47-mediated neutrophil transmigration may be protec-
tive in the acute phase of disease. However, a previously pub-
lished report has suggested a protective role for neutrophils in 
disease initiation (Kühl et al., 2007). Therefore, although a 
reduction of neutrophil infiltration was observed in CD47 
KO mice, we largely excluded this phenomenon as playing a 
protective role in the development of TNBS colitis.
In the present study, we observed causative links between 
an  increased  percentage  of  SIRP+CD103  DCs,  Th17-
skewed responses, and disease manifestation, suggesting a role 
for Th17 cells in the development of colitis. The in vitro 
Th17-promoting  capacity  of  CD11cHiSIRP+CD103 
DCs  seems  to  be  shared  by  the  previously  described 
CD11cHiCX3CR1
+CD103 LP DC subset, supporting their 
contribution in the initiation of Th17 responses (Denning   
et al., 2007). Until recently, both CD and TNBS colitis have 
been considered Th1 diseases characterized by IL-12, TNF-
, and IFN- production (Neurath et al., 1995; Parronchi   
et  al.,  1997).  However,  several  recent  observations  have 
strongly implicated a role for IL-23, a Th17 survival factor, 
and Th17 cells in disease pathogenesis. In humans, elevated 
serum levels of IL-17 and colonic mucosal levels of both IL-
17 and IL-23 have been detected in CD patients (Fujino   
et al., 2003; Schmidt et al., 2005), whereas a mutation in   
the IL-23R gene (rs11209026, c.1142G>A, p.Arg381Gln) is 
protective from disease development (Duerr et al., 2006). It 
is established that the intestinal mucosal environment, via 
TGF-, thymic stromal lymphopoietin, and IL-10, acts to 
condition resident antigen-presenting cells to exert immuno-
suppressive activities (Jarry et al., 2008; Zeuthen et al., 2008). 
Epithelial cells from CD patients express less thymic stromal 
lymphopoietin, leading to an enhanced release of the pro-
Th1 and -Th17 inflammatory cytokines IL-12, IL-6, and IL-
23, and expression of TLR2 and TLR4 by DCs (Hart et al., 
2005; Rimoldi et al., 2005). Moreover, the combination of 
subset in both the tissues and mLNs. Yet, CD47 KO mice do 
not  display  any  change  in  the  proportion  of  tolerogenic 
CD103+ DCs in mLNs upon exposure to TNBS, and a single 
administration of WT SIRP+CD103 DCs in CD47 KO 
mice was sufficient to induce severe wasting disease. Conse-
quently,  our  data  support  a  proinflammatory  role  for  the 
SIRP+CD103 DC subset, the effect of which may be am-
plified by, but is not exclusively dependent on, the reduction 
in the proportion of tolerogenic CD103+ DCs in the mLNs. 
In support of this concept, CD103+ DCs are found in equal 
proportions  in  the  mLNs  draining  the  small  intestines  of 
healthy individuals and those of CD patients, implying that 
intestinal inflammation is not dependent on a reduction in 
CD103+ DCs (Jaensson et al., 2008).
In the gut, CCR7 largely controls CD103+ DC traffick-
ing at steady state (Jang et al., 2006; Worbs et al., 2006). We 
have previously reported that the absence of CD47 does not 
alter  CCR7  expression  or  the  in  vitro  migration  of  skin 
SIRP+  DCs  toward  CCL19  or  sphingosine-1-phosphate 
(Van  et  al.,  2006).  The  reduced  proportion  of  the 
SIRP+CD103 DC subset in the mLNs of CD47 KO and 
CD47-Fc–treated mice upon exposure to TNBS strongly 
suggests that CD47 promotes this process. These findings 
corroborate previous in vivo studies in which a reduction of 
SIRP+ DCs was observed in skin-draining LNs of CD47 
KO and CD47-Fc–treated mice, which was found to be in-
dependent of CD47 expression on lymphatic vessels (Van   
et al., 2006). In support of these findings, we demonstrate in 
this paper that injected WT SIRP+CD103 DCs migrate 
more efficiently to mLNs and elicit a more aggressive form of 
disease in CD47 KO hosts when compared with CD47 KO 
DCs. However, the underlying mechanisms by which CD47 
governs SIRP+CD103 DC migration remains to be eluci-
dated. One hypothesis is that CD47–SIRP interactions that 
may occur in cis on the DC indirectly control integrin-medi-
ated transendothelial trafficking.
The expression of CD62L on CD103 DCs (Johansson-
Lindbom et al., 2005) and a more recent report examining 
the turnover of intestinal DC subsets (Jaensson et al., 2008) 
favor the hypothesis of a direct recruitment of CD103 DCs 
or their precursors from the bloodstream to the mLNs via 
high endothelial venules at steady state. Our study supports 
this hypothesis, because there is no defect of SIRP+CD103 
DCs in the LP, whereas there is a significant reduction in 
the proportion of these DCs in the mLNs of CD47 KO 
mice at steady state. Therefore, SIRP+CD103 DCs or 
their precursors may bypass the LP to seed the mLNs in a 
CD47-dependent manner. However, during the induction 
of colonic inflammation, SIRP+CD103 DCs or their pre-
cursors may be recruited de novo to inflamed tissues before 
migrating to the mLNs. Interestingly, under inflammatory 
conditions, CX3CR1intGR1highCD62L+CCR2+ monocytes 
(GR1high monocytes) have been shown to differentiate into 
LP DCs (Varol et al., 2007), but i.v.-injected bone marrow 
monocytes are also capable of directly entering LNs through   
high endothelial venules (Nakano et al., 2009). Thus, under JEM VOL. 206, August 31, 2009 
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contribute to IL-6 production during colitis (Dann et al., 
2008; Mudter et al., 2008). We demonstrate in this paper that 
CD47  expression  does  not  regulate  IL-6  production  by 
SIRP+CD103 DCs. Therefore, the reduction of IL-6 ex-
pression observed in this study likely reflects an indirect con-
sequence of reduced tissue infiltration.
To eliminate the developmental alterations in CD47   
KO mice, such as the expansion of the CD103+ T reg cell 
population (Van et al., 2008) and Th1-biased phenotype 
(Bouguermouh et al., 2008), as a potential explanation for dis-
ease resistance, we demonstrate that the short-term interruption 
of CD47 ligation by the administration of a CD47-Fc molecule 
protected WT BALB/c mice from disease development. At an 
early time point after disease induction, we readily observed a 
reduced proportion of SIRP+CD103 DCs in the mLNs 
and an inverted IL-17/IFN- mRNA ratio in treated com-
pared with untreated mice. The therapeutic efficacy of CD47-
Fc could not be attributed to increased T reg cell activity, 
because CD4+CD25+FoxP3+ T reg cell numbers were posi-
tively correlated with inflammation and were lower in CD47-
Fc–treated mice (unpublished data). Finally, early administration 
of CD47-Fc was shown to be highly effective in preventing 
both disease initiation and the recurrence of colitis after a sec-
ond TNBS challenge. In that respect, the therapeutic efficacy 
of most published compounds has only been assessed in the 
prevention of acute disease (te Velde et al., 2006).
In conclusion, we have identified SIRP+CD103 DCs 
as an immunogenic Th17-inducing DC subset and propose 
their role in the pathogenesis of TNBS-induced colitis. We 
further demonstrate that CD47 expression on SIRP+CD103 
DCs promotes their trafficking and the development of se-
vere intestinal inflammation. We therefore propose that tar-
geting the CD47–SIRP axis may serve as the basis for the 
development of novel therapeutic strategies in CD.
MATERIALS AND METHODS
Animals
6–8-wk-old WT BALB/c and BALB/c CD47 KO mice were bred and 
maintained in our animal care facility in standard animal cages and under 
specific pathogen-free conditions. CD47 KO mice are viable and do not ex-
hibit any overt phenotype. All mice were handled according to institution-
ally recommended animal care guidelines, and all experiments were approved 
by the Animal Studies Ethics Committee of McGill University and the Cen-
tre de Recherche du Centre Hospitalier de Montreal.
Culture medium, antibodies, and reagents
Ex vivo and in vitro experiments were performed using complete RPMI 
1640 medium (Wisent Inc.) supplemented with 10% fetal calf serum (Wisent 
Inc), 500 U/ml penicillin, 500 µg/ml streptomycin, 10 mM Hepes buffer, 
and 1 mM 2-mercaptoethanol (Invitrogen). IMDM (Invitrogen) supple-
mented with 5% fetal calf serum, 500 U/ml penicillin, 500 µg/ml strep-
tomycin, and 1 mM 2-mercaptoethanol was used for in vitro CD4+ T cell 
co-cultures with sorted DCs. Escherichia coli LPS was obtained from Sigma-
Aldrich, and GM-CSF was purchased from PeproTech. The anti-CD3 anti-
body (145-2C11) used for in vitro polyclonal stimulation was obtained from 
BD. Allophycocyanin (APC)-labeled anti-CD4, FITC-labeled anti–IFN-, 
and PE-labeled anti–IL-17 were used for intracytoplasmic cytokine staining 
of CD4+ T cells and were obtained from BD. For DC phenotype staining and 
DC/CD4+ T cell sorting, FITC-labeled anti-CD11b, anti–MHC II, anti-
CD40, and anti-CD86, PE-labeled anti-SIRP, biotinylated anti-CD103 
intestinal epithelial-derived TGF- and retinoid acid has also 
recently been shown to convert CD103 DCs into CD103+ 
DCs capable of generating T reg cells (Iliev et al., 2009). IL-
23 is abundantly produced by ileal but not colonic mouse 
DCs (Becker et al., 2003). Therefore, TNBS colitis, a model 
in which the inflammation is localized to the colon, might be 
less suitable than others for examining IL-23 regulation, as 
underscored by the low colonic mRNA expression of IL-
23p19 in this study, even under conditions of severe inflam-
mation. Nonetheless, the expression of IL-17 was strongly 
up-regulated by TNBS in WT mice as compared with CD47 
KO mice. IL-17 is considered to be pathogenic in TNBS 
colitis  because  IL-17R–deficient  mice  are  protected  from 
disease  development,  and  administration  of  an  anti–IL-17 
mAb ameliorates intestinal inflammation despite high levels 
of IFN- (Zhang et al., 2006). In contrast, IFN- receptor– 
and IFN-–deficient mice, or mice administered a neutraliz-
ing anti–IFN- mAb developed colitis as severe as WT mice 
(Camoglio et al., 2000; Tozawa et al., 2003), suggesting that 
IFN- and IL-12 play a less essential role in disease develop-
ment than once believed. On the other hand, both IL-17 and 
IFN- synergize to create intestinal inflammation in Helico-
bacter  hepaticus–induced  T  cell–dependent  colitis  (Kullberg   
et al., 2006). In Th17-associated autoimmune diseases, such 
as experimental autoimmune uveitis (Luger et al., 2008) and 
experimental autoimmune encephalomyelitis, either Th1 or 
Th17 cells alone can drive tissue damage (Bettelli et al., 2004; 
Kroenke et al., 2008; Stromnes et al., 2008). T cell clones 
isolated from CD patients have been identified as being ei-
ther single IL-17+ or double IL-17+IFN-+ cells, under-
scoring the potentially pathogenic role of both cytokines 
(Annunziato et al., 2007). Some studies have even suggested 
a differential role for Th1 versus Th17 cells at various stages 
of disease (Kobayashi et al., 2008). Moreover, the develop-
mental plasticity of Th17 cells has been reported, whereby 
IL-23  and  IL-12  convert  terminally  differentiated  mouse 
Th17 cells into IFN-–producing cells (Lee et al., 2009). 
Thus, it is likely an oversimplification to implicate Th17 cells 
alone in the development of TNBS colitis, and as such, we 
monitored the Th17/Th1 ratio rather than an exclusive de-
crease in the frequency of Th17 cells as a common thread of 
disease protection throughout this study. Finally, although 
Th17 cells are often categorized as pathogenic in autoim-
mune disease, it should be emphasized that they critically 
participate in protecting the host from microbial invasion and 
maintaining the epithelial barrier, as was demonstrated for the 
Th17-associated cytokine IL-22 (Mudter et al., 2008).
We also report that the mRNA expression of IL-6, a key 
Th17 cell differentiation factor, was impaired in the colon tis-
sues of protected mice. IL-6 plays an important role in both T 
cell–dependent and –independent models of colitis (Atreya   
et al., 2000; te Velde et al., 2007), and IL-6–deficient mice were 
reported to show resistance to TNBS-induced colitis (Atreya 
et al., 2000; Gay et al., 2006). Although the precise cellular 
source of IL-6 was not examined in this study, epithelial cells 
and T cells themselves, in addition to antigen-presenting cells, 2008 CD47 GOVERNS SIRP+ DC HOMING AND COLITIS | Fortin et al.
DC phenotype in LP and mLNs
LP cells were isolated as previously described (Drakes et al., 2004). In brief, co-
lons were extracted, thoroughly cleaned, and digested in a solution of collage-
nase IV (Roche) and DNase I (Roche). mLNs were harvested 2 d after primary 
TNBS instillation and treated with 0.7 mg/ml Liberase (Roche) for 15 min at 
37°C. 4 × 106 cells were stained with anti-CD45.2, anti-CD11c, anti-CD11b, 
anti-SIRP, and anti-CD103 antibodies and analyzed by flow cytometry. Data 
were acquired on a FACSAria II (BD) and analyzed with CellQuest software.
Generation of BMDCs
BMDCs were generated from bone marrow as previously described (Van   
et al., 2006). In brief, bone marrow was harvested from WT and CD47 KO 
mice and cultured in RPMI 1640 supplemented with 5% FBS, 500 U/ml 
penicillin, 500 µg/ml streptomycin, 1 mM 2-mercaptoethanol, and 40 ng/
ml GM-CSF, which was replenished on days 3, 7, and 12. BMDCs were 
harvested on day 13.
In vitro and in vivo assessment of DC function
In vitro. WT BALB/c mice were injected with 10 µg of human Flt3-L 
daily for 13 d to increase DC numbers. LP and mLN cells were purified 
as described, and cells were isolated from spleens using the same Liberase 
digestion protocol as mLNs. All cells were stained with anti-CD11b, anti-
SIRP, anti-CD103, anti-CD11c, anti-CD45.2, and anti-CD4, and sorted 
using a FACSAria II (Fig. S2 shows the gating strategy). The purity of CD4+ 
T cells and DC subsets was >99% and >96%, respectively. CD4+ T cells 
were co-cultured for 5 d with sorted SIRP+CD103 or SIRPCD103+ 
DCs at a 25:1 ratio in the presence of soluble 2 µg/ml anti-CD3, 2 ng/
ml TGF-, and 10 µg/ml anti–IFN-. Transgenic (D011.10) CD4+ T cells 
were co-cultured with BMDCs (1:2 ratio) in the presence of 2 µg/ml OVA 
peptide, 2 ng/ml TGF-, and 10 µg/ml anti–IFN-. On day 5, 5 ng/ml 
PMA, 0.5 µg/ml ionomycin, and 1 µg/ml Brefeldin A were added to the cell 
cultures, and intracytoplasmic staining for IL-17 and IFN- was performed 
as described above.
WT and CD47 KO BMDCs were stimulated with 100 ng/ml LPS and 
the expression of CD11c, CD11b, CD103, and SIRP, and the activation 
markers CD86, CD40, and MHC II were assessed after overnight culture by 
flow cytometry. To assess cytokine production (IL-6 and IL-23p19), BM-
DCs were stimulated overnight with 100 ng/ml LPS in the presence of 10 
ng/ml IFN-. For WT/CD47 KO BMDC/T cell criss-cross co-cultures, 
splenic CD4+ T cells were purified using the EasySep Biotin Selection Kit 
(StemCell Technologies Inc.). Anti-CD3–stimulated (2 µg/ml) CD4+ T 
cells were co-cultured with LPS-stimulated (500 ng/ml) BMDCs at a 10:1 
(T cell/DC) ratio in the presence of 1 ng/ml TGF-. After 5 d, cells were 
restimulated  with  PMA/ionomycin  in  the  presence  of  Brefeldin  A  and 
stained for intracytoplasmic IL-17.
In vivo. LPS-stimulated (500 ng/ml) WT and CD47 KO BMDCs were 
harvested and transferred to CD47 KO hosts by i.p. injection of 2 × 106 
cells per mouse 30 min before induction of TNBS colitis (Gonzalez-Rey 
and Delgado, 2006).
Competitive DC migration assay
WT and CD47 KO BMDCs were stimulated with 500 ng/ml LPS over-
night and labeled with CFSE (WT) or CMTMR (CD47 KO) and injected 
i.p. in CD47 KO hosts. TNBS colitis was induced 30 min after DC injec-
tion, and mLNs were harvested on day 2 from host mice to assess DC mi-
gration. mLNs were digested with 0.7 mg/ml Liberase for 15 min at 37°C, 
and cells were analyzed by gating on CD11c+ cells by flow cytometry.
Statistical analyses
Statistical  analyses  were  performed  using  the  Instat  program  (GraphPad   
Software, Inc.). All values are expressed as means ± SEM. The Student’s t 
test, paired t test, and Mann-Whitney U test were used to assess statisti-
cal significance.
plus  streptavidin-PerCP,  APC-labeled  anti-CD11c,  anti-CD45.2–APC–
Cy7, and anti-CD4–PeCy7 were obtained from BD.
TNBS-induced colitis
Two different models of chronic TNBS colitis were induced. In the first 
model, 3 mg TNBS (Sigma-Aldrich) was dissolved in 50% ethanol and a total 
volume of 50 µl was injected intrarectally in isopropanol-anesthetized mice 
(Scheiffele and Fuss, 2002). Controls included those administered intrarectal 
saline or ethanol alone. Mice were sacrificed 8 d after TNBS injection to assess 
colonic inflammation. The second form of chronic TNBS colitis was induced 
by two injections of 2 mg TNBS dissolved in 50% ethanol. The second injec-
tion was administered 7 or 8 d after the primary injection. Mice were sacrificed 
either 2 d after primary TNBS injection to assess early events in disease devel-
opment or 4 d after the secondary injection to assess colonic inflammation.
For treatment of TNBS colitis, 100 µg of mouse CD47-Fc (Van et al., 
2006), control human CD47-Fc (Latour et al., 2001), or saline was injected 
i.p. on days 0–3, inclusively. 2 mg TNBS colitis was induced on days 0 and 
8, and mice were sacrificed on day 4 or 12. In all cases, the macroscopic 
score of inflammation was assessed based on the degree of ulceration (0–10), 
the presence of diarrhea (0–1) and adhesions (0–2), and on the thickness of 
the colon wall (0–1). For histological assessment, colon samples were em-
bedded in optimum cutting temperature compound (Sakura Finetek) and 
stained with hematoxylin and eosin. Histological changes were semiquanti-
tatively graded based on a set of previously established criteria (Ameho et al., 
1997). The grading scale ranged from 0–16 and was calculated as the sum of 
scores for expansion of submucosa (0–4), expansion of LP (0–4), loss of gob-
let cells (0–4), and neutrophil infiltration (0–4). All macroscopic and micro-
scopic scoring was performed in a blinded fashion.
Cytokine quantification by ELISA
Whole blood was withdrawn from mice immediately postmortem and sera 
were frozen at 20°C until use. Serum IL-6 was quantified by the Quanti-
kine ELISA kit (R&D Systems). IL-6 and IL-23p19 production was assessed 
in BMDC culture supernatants after overnight culture using the mouse IL-6 
DuoSet (R & D Systems) and IL-23p19 (eBioscience) ELISA kits.
Real-time PCR
Colons were immediately immersed in RNAlater (QIAGEN) upon dissec-
tion and frozen at 20°C until use. mRNA was extracted according to 
the TRIzol protocol and was reverse transcribed using the cDNA RT kit 
(Applied Biosystems). Quantitative real-time PCR was performed using a 
sequence detection system (1 PCR cycle at 95°C for 10 min; 40 PCR cycles   
at 60°C for 1 min and at 95°C for 15 s; ABI Prism 7900HT; Applied   
Biosystems). cDNA was amplified in a 10-µl final reaction mix containing 
TaqMan Universal PCR Master Mix (Applied Biosystems) and the corre-
sponding  TaqMan  gene  expression  assays  (IL-6,  Mm00446190_m1;  Eu-
karyotic 18s rRNA, Hs99999901_s1; IL-17a, Mm00439619_m1; IL-12p35, 
Mm00434165_m1;  thrombospondin-1,  Mm00449022_m1;  IL-23p19, 
Mm00518984_m1; IFN-, Mm00801778_m1; TGF-, Mm00441724_m1; 
Applied Biosystems). Signals were analyzed by the ABI Prism sequence de-
tection system software (version 2.2; Applied Biosystems). The comparative 
Ct method for relative quantification was used, whereby all Ct were first 
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